

Poster session 2 Thursday 7-9 AM

- P2-01-01** Trajectory patterns of circulating tumor cells (CTC) in chemotherapy-treated metastatic breast cancer (MBC) patients predict poor clinical outcomes: CALGB 40502 (Alliance)/NCCTG N063H study
Magbanua MJ, Hendrix L, Hyslop T, Barry WT, Winer EP, Hudis C, Toppmeyer D, Burnstein H, Qadir M, Ma C, Scott JH, Park JW, Rugo HS.
- P2-01-02** Heterogeneity and variability of human epidermal growth factor receptor 2 (HER2) expression on circulating tumor cells (CTC) in HER2 negative metastatic breast cancer patients treated with first line weekly paclitaxel and bevacizumab in a prospective cohort from the French Breast Cancer InterGroup Unicancer (UCBG): COMET study
Pierga J-Y, Proudon C, Tredan O, Decraene C, Dubot C, Lorgis V, Jacot W, Goncalves A, Debled M, Levy C, Ferrero J-M, Jouannaud C, Luporsi E, Mouret-Reynier M-A, Dalenc F, Lemonnier J, Berger F, Bidard F-C.
- P2-01-03** Improved prognostic information by serial monitoring of CTC enumeration and CTC-clusters from baseline to six months in patients with metastatic breast cancer scheduled for 1st line systemic therapy
Larsson A-M, Jansson S, Bendahl P-O, Baker S, Graffman C, Lundgren C, Loman N, Aaltonen KE, Rydén L.
- P2-01-04** The whole transcriptional landscape of circulating tumor cells compared to metastases in stage IV breast cancer
Ring A, Porras T, Campo D, Kaur P, Forte VA, Tripathy D, Lu J, Zada G, Wagle N, Wechsler JS, Lang JE.
- P2-01-10** Circulating CAF/CTC complexes and breast cancer metastasis
Miller P, Sharma U, Medina-Saenz K, Yeasky T, Picon-Ruiz M, Morata-Tarifa C, Seagroves T, Slingerland J, Lippman M, El-Ashry D.
- P2-02-06** Biomarker analysis by next generation circulating tumor DNA (ctDNA) sequencing in patients with advanced breast cancer
Li H, Wang J, Rugo HS, Zhang Y, Yang L, Liu X, Shao B, Xu Y, Yang L, Zhang R, Ran R, Chang L.
- P2-02-10** Circulating level of GP88/Progranulin is associated with clinical outcome and overall survival in stage 4 breast cancer patients
Serrero G, Hawkins D, Hicks D, Rosenblatt P, Tait N, Yue B, Tkaczuk K.
- P2-02-11** Circulating HER2 extracellular domain (ECD) predicts a poor prognosis for metastatic breast cancer
Shao X, Wang X, Huang P, Li G, Zou W, Chen Z, Zheng Y.
- P2-02-15** Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer
Banys-Paluchowski M, Fehm T, Janni W, Aktas B, Fasching PA, Kasimir-Bauer S, Milde-Langosch K, Pantel K, Rack B, Riethdorf S, Solomayer E-F, Witzel I, Müller V.
- P2-02-16** Use of cell-free circulating RNA and expression of PD-L1 and HER2 in plasma to monitor and predict clinical response in metastatic breast cancer patients
Castrellon AB, Velez M, Raez LE, Danenberg K, Rabizadeh S, Usher J, Jaimes Y, Hunis B, Bittencourt AC, Milillo A, Blaya M, Habaue C, Danenberg PV.
- P2-02-17** Circulating tumor DNA analysis with ultra-high sensitivity sequencing in metastatic breast cancer
Garcia-Murillas I, Proszek P, Fribbens C, Yuan L, Bye H, Hubank M, Jiang J, Yuang S, Palma J, Johnston S, Ring A, Turner N.
- P2-02-18** Higher mutation burden and mutant allele fraction of circulating tumor DNA corresponds to worse progression free survival in metastatic breast cancer patients
Keenan T, Juric D, Niemierko A, Spring L, Park H, Malvarosa G, Beeler M, Moy B, Ellisen L, Isakoff S, Bardia A.

- P2-05-07** Whole exome sequencing of extreme responders reveals low mutation burden in metastatic breast cancer
Sohn J, Lim SM, Kim E, Kim S, Koo JS, Kim SI, Park S, Park HS, Kwon N-J, Kim GM, Kim S.
- P2-09-16** Tumor infiltrating lymphocytes (TILs) as a biomarker for resistance to palbociclib (Pal) in the NeoPalAna trial
Sanati S, Barve R, Luo J, Hoog J, Head R, Ellis M, Ma C.
- P2-09-19** Genomic biomarker for resistance to palbociclib in the NeoPalAna trial
Hoog JW, Treece T, Blumencranz L, Audeh W, Sanati S, Ellis MJ, Ma CX.
- P2-09-20** Biomarker analysis of the LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) in metastatic triple-negative breast cancer (TNBC)
Wongchenko MJ, Dent R, Kim S-B, Saura C, Oliveira M, Baselga J, Kapp AV, Chan WY, Singel SM, Maslyar DJ, Gendreau S.
- P2-09-26** Frequency and mechanisms of elevated somatic mutation burden in metastatic breast cancer and response to immune checkpoint blockade
Cobain EF, Robinson DR, Wu Y-M, Lonigro R, Vats P, Rabban E, Kumar-Sinha C, Schott AF, Smerage JB, Morikawa A, Burness ML, Van Poznak CH, Griggs J, Wicha M, Hayes DF, Chinnaiyan AM
- P2-09-31** Predictive impact of absolute lymphocyte counts for progression-free survival in HER2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel
Araki K, Ito Y, Fukada I, Kobayashi K, Ohno S, Miyagawa Y, Imamura M, Kira A, Takatsuka Y, Egawa C, Suwa H, Miyoshi Y.
- P2-10-02** Basal biomarkers nestin and INPP4b predict gemcitabine benefit in metastatic breast cancer: Results from the phase III SBG0102 clinical trial
Asleh-Aburaya K, Lyck Carstensen S, Burugu S, Gao D, Tykjær Jørgensen C, Won JR, Jensen M-B, Balslev E, Lærnholm A-V, Nielsen DL, Ejlertsen B, Nielsen TO.